Pharmaceuticals remain the least invasive and most cost-effective means of patient treatment, and represent a substantially important factor in the potential reductionof long-term, overall healthcare costs. The pharmaceutical industry continues to evolve within a transitional environment as most of the elements affecting its core business have changed. Drug companies are confronting the consequences of managed care, increased pricing pressures, generic competition, and overall margin shrinkage. In response, they are vigorously seeking new ways to increase profitability, differentiate their products, and add depth and diversity to their product lines. One of these alternatives is to exploit improvements upon the method of drug delivery.